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Abstract
Viral fusogenic envelope proteins are important targets for the development of inhibitors of viral entry. We report an
approach for the computational design of peptide inhibitors of the dengue 2 virus (DENV-2) envelope (E) protein using
high-resolution structural data from a pre-entry dimeric form of the protein. By using predictive strategies together with
computational optimization of binding ‘‘pseudoenergies’’, we were able to design multiple peptide sequences that showed
low micromolar viral entry inhibitory activity. The two most active peptides, DN57opt and 1OAN1, were designed to
displace regions in the domain II hinge, and the first domain I/domain II beta sheet connection, respectively, and show fifty
percent inhibitory concentrations of 8 and 7 mM respectively in a focus forming unit assay. The antiviral peptides were
shown to interfere with virus:cell binding, interact directly with the E proteins and also cause changes to the viral surface
using biolayer interferometry and cryo-electron microscopy, respectively. These peptides may be useful for characterization
of intermediate states in the membrane fusion process, investigation of DENV receptor molecules, and as lead compounds
for drug discovery.
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Introduction
Fusogenic viral envelope glycoproteins are multimeric proteins
that facilitate the fusion of viral and target cell lipid membranes
during the initiation of infection. The membrane fusion process is
energetically favorable and essentially irreversible, but has a
considerable kinetic energy barrier [1]. These proteins allow rapid
membrane fusion by drawing the opposing membranes together
and either stabilizing or providing the activation energy to
surmount the transition state [1,2]. In this way, they behave in
many aspects like a fusion catalyst. Because they effect a
macromolecular process that involves large scale conformational
changes in the substrate membranes and the proteins themselves,
these proteins possess multiple interacting surfaces that could be
targeted by inhibitors [3].
There are several distinct types of viral fusion proteins,
including the class I, primarily alpha helical proteins (such as
HIV TM and influenza HA), the class II, primarily beta sheet
proteins (such as the flavivirus E and alphavirus E1), and mixed
helix/sheet proteins (including herpes virus gB and rhabdovirus G)
[3,4]. To date, most progress with viral fusion protein inhibitors
has focused on class I alpha helical proteins. The HIV TM protein
provides an excellent example of targeting distinct, interacting
surfaces for inhibition. The HIV TM functions as a homotrimer
with each monomer contributing two alpha helical regions that
interact to form a post-fusion six-helix bundle. Inhibition of the
formation of this six-helix bundle can be accomplished by
exogenous peptides mimicking either of the two reciprocally
interacting helices [5–7].
Only a few examples of viral entry inhibitors with activity
against the primarily beta sheet envelope proteins (E) from
flaviviruses have been described [8–10]. However, few of these
have taken advantage of the available crystal structures of
flavivirus E proteins, including both pre-fusion and post-fusion
forms [11–22]. The authors of some of these structures have
predicted that several regions of these proteins might be targets
www.plosntds.org 1 June 2010 | Volume 4 | Issue 6 | e721for inhibition [11,14,15]. Here we report the use of structural
data from the pre-fusion dengue virus-2 (DENV-2) E protein as
a model for a computational approach to the design of new
peptide inhibitors of DENV-2 entry. This approach makes use
of a residue-specific all-atom probability discriminatory func-
tion (RAPDF) score to identify in situ amino acid sequences that
are likely to have high structural and binding stability [23,24].
Out of seven computationally designed peptides that were
synthesized and tested, two were identified as possessing fifty
percent in vitro inhibitory activity (IC50) below 10 mMa n d
another with IC50 activity below 40 mM. Two of the inhibitors
(DN57opt and DN81opt) are binding optimized variants of
peptides originally designed from DENV inhibitory peptide
sequences located in domain II near the domain I/domain II
hinge region [9]. The other (1OAN1) is an entirely novel
peptide designed from an extended beta sheet region compris-
ing the first connection between domains I and II. We show
that the two peptides with the highest inhibitory activity
interfere with virus:cell binding, cause structural changes to the
surface of DENV-2 virions, and bind specifically to purified
DENV-2 E protein.
The causative agent of dengue fever, dengue hemorrhagic fever
and dengue shock syndrome, DENV has emerged in the past
several decades as the most important mosquito borne viral disease
with an estimated 2.5 billion people living in areas at risk for
epidemic transmission and 50–100 million people infected
annually [25,26]. Complicating this situation, the four distinct
serotypes of DENV generate only low level immunological cross
protection, allowing for repeated epidemic outbreaks in the same
populations [27,28]. The phenomenon of antibody dependent
enhancement has been shown to result in more severe disease in
individuals who have been previously infected with a different
serotype [29–33]. With no specific treatment or prevention
available other than vector control, DENV is an important target
for the development of antivirals and vaccines. The results
presented here indicate that the DENV E glycoprotein has
multiple accessible surfaces that can be targeted by distinct
inhibitors and is an amenable target for rational inhibitor
design.
Materials and Methods
Computational optimization of hinge region inhibitory
peptides
Peptide inhibitors were designed to have improved in situ binding
compared to naturally occurring sequences using the residue-
specific all-atom probability discriminatory function (RAPDF) [24].
The x-ray diffraction structure of DENV-2 envelope protein
(Protein Data Bank identifier 1OAN) was used as a template for
creating mutant structures from which the peptides were derived
[14]. For each peptide, we randomly selected a residue side chain
and substituted it with a new side chain. The substitution was
performed using a backbone-dependent side chain rotamer library
and a linear repulsive steric energy term provided by SCWRL
version 3.0 [34]. The resulting all-atom models were energy
minimized for 200 steps using the Energy Calculation and
Dynamics (ENCAD) program [35–37]. RAPDF scores were then
calculated to estimate the structural stability of a given E protein
structure derivative. For a selected residue, side chain substitution
was carried out ten times. The amino acid that produced the best
RAPDF score was selected and used as a template for further
mutation. The entire mutation process was repeated 100,000 times
to enable a rigorous search for peptides that produced the best
RAPDF score (i.e., highest predicted stability).
Computational design of novel inhibitory peptides
A 20 residue acid sliding window that moved from the N to the
C terminus of the E protein in 10 residue acid increments was
evaluated by a structural stability (pseudoenergy) optimization
protocol using the RAPDF. A Metropolis Monte Carlo search
algorithm [38] was used to change each amino acid in the 20
residue window to one of the other 19 naturally occurring amino
acids, and the stability of corresponding peptide in the context of
the entire E protein structure was evaluated. This process was
iterated 100,000 times using RAPDF as the target scoring
function. The Metropolis criterion was used to select a particular
change in the simulation: if a particular change resulted in a better
RAPDF score (lower pseudoenergy), then it was retained. If a
particular change resulted in a worse RAPDF score (higher
pseudoenergy), then a random choice, based on the score
difference between the previous change and the current one,
was made to retain the corresponding change. This procedure
enables not only enables design of peptides that will result in high
structural and binding stability (i.e., the best RAPDF scores/
pseudoenergies), but also enables surmounting local minima
encountered during the search. Computational optimization was
performed on the four regions corresponding to the best RAPDF
score, and therefore the highest binding potential, within the E
protein as described above to generate variant peptides sequences.
Viruses and cells
DENV-2 strain NG-C was obtained from R. Tesh at the
University of Texas at Galveston. Virus was propagated in the
Macaca mulatta kidney epithelial cell line, LLC-MK2 (ATCC
catalog number CCL-7). Cells were grown in Dulbecco’s modified
eagle medium (DMEM) with 10% (v/v) fetal bovine serum (FBS),
2 mM Glutamax, 100 U/ml penicillin G, 100 mg/ml streptomy-
cin and 0.25 mg/ml amphotericin B, at 37uC with 5% (v/v) CO2.
Peptides
Peptides were synthesized by solid-phase N-a-9-flurenylmethy-
loxycarbonyl chemistry, purified by reverse-phase high perfor-
mance liquid chromatography and confirmed by amino acid
analysis and electrospray mass spectrometry (Genemed Synthesis,
Author Summary
Virus surface proteins mediate interactions with target
cells during the initial events in the process of infection.
Inhibiting these proteins is therefore a major target for the
development of antiviral drugs. However, there are a very
large number of different viruses, each with their own
distinct surface proteins and, with just a few exceptions, it
is not clear how to build novel molecules to inhibit them.
Here we applied a computational binding optimization
strategy to an atomic resolution structure of dengue virus
serotype 2 envelope protein to generate peptide sequenc-
es that should interact strongly with this protein. We
picked dengue virus as a target because it is the causative
agent for the most important mosquito transmitted viral
disease. Out of a small number of candidates designed and
tested, we identified two different highly inhibitory
peptides. To verify our results, we showed that these
peptides block virus:cell binding, interfere with a step
during viral entry, alter the surface structure of dengue
viral particles, and that they interact directly with dengue
virus envelope protein. We expect that our approach may
be generally applicable to other viral surface proteins
where a high resolution structure is available.
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(v/v) dimethyl sulfoxide (DMSO): 80% (v/v) H2O, and concen-
trations determined by absorbance of aromatic side chains at
280 nm.
Focus forming unit assay
LLC-MK2 target cells were seeded at a density of 1610
5 cells in
each well of a 6-well plate 24 h prior to infection. Approximately 200
focus forming units (FFU) of virus were incubated with or without
peptide in serum-free DMEM for 1 h at rt. Virus/peptide or virus/
control mixtures were allowed to infect confluent target cell
monolayers for 1 h at 37uC, with rocking every 15 m, after which
timethe medium was aspirated and overlaid with fresh DMEM/10%
(v/v) FBS containing 0.85% (w/v) Sea-Plaque Agarose (Cambrex Bio
Science, Rockland, ME) without rinsing. Cells with agar overlays
were incubated at 4uC for 20 m to set the agar. Infected cells were
then incubated at 37uCw i t h5 %C O 2 for 5 days. Infected cultures
were fixed with 10% formalin overnight at 4uC, permeablized with
70% (v/v) ethanol for 20 m, and rinsed with phosphate buffered
saline, pH 7.4 (PBS) prior to immunostaining. Virus foci were
detected using a specific mouse mAb from hybridoma E60 (obtained
from M. Diamond at Washington University), followed by
horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
(Pierce, Rockford, IL), and developed using AEC chromogen
substrate (Dako, Carpinteria, CA). Results are expressed as the
average of at least two independent trials with three replicates each.
IC50 values were determined using variable slope sigmoidal dose-
response curve fits with GraphPad Prism 4.0 software (LaJolla, CA),
except for DN81opt, which was determined graphically due to a lack
of data points to produce a reasonable curve fit.
Toxicity assay
Cytotoxicity of peptides was measured by monitoring mito-
chondrial reductase activity using the TACS
TM MTT cell
proliferation assay (R&D Systems, Inc., Minneapolis, MN)
according to the manufacturer’s instructions. Dilutions of peptides
in serum-free DMEM were added to confluent monolayers of
LLC-MK2 cells in 96-well plates for 1 h at 37uC, similar to the
focus forming inhibition assays, and incubated at 37uC with 5%
(v/v) CO2 for 24 h. Absorbance at 560 nm was measured using a
Tecan GeniosPro plate reader (Tecan US, Durham, NC).
Cryoelectron microscopy
DENV-2 NGC strain used for the cryoEM reconstructions was
propagated in mosquito C6/36 cells. Virus was purified by
precipitation with 40% PEG 8000 and then ultracentrifugation
onto a 25% sucrose cushion. Virus was further purified by banding
on a 10%–30% potassium tartrate gradient. The virus band was
removed and dialyzed against 12 mM Tris pH 8.0, 120 mM
NaCl, 1 mM EDTA, and concentrated using a Millipore
Centricon filter. Purified virus was mixed with 1OAN or DN57opt
at a concentration of 1 molecule of peptide for every E protein on
the surface of the virus. The complex was incubated for half an
hour at 37uC followed by half an hour at 4uC and then flash frozen
on holey carbon grids in liquid ethane. Images of the frozen
complex were taken with a Philips CM200 FEG transmission
electron microscope (Philips, Eindhoven, The Netherlands) at a
magnification 51,040 using an electron dose of approximately,
25e-/A ˚ 2 using a Charge-Couple device.
Peptide:E protein biolayer interferometry binding assay
Real time binding assays between peptides and purified DENV-2
S1 E protein were performed using biolayer interferometry on an
Octet QKsystem(Fortebio,MenloPark,CA).This systemmonitors
interference of light reflected from the surface of a fiber optic sensor
to measure the thickness of molecules bound to the sensor surface.
Purified, recombinant, 80% truncated DENV-2 S1 E protein was
obtained from Hawaii Biotechnology (Honolulu, HI). Peptides were
N-terminally biotinylated with a 5:1 molar ratio of NHS-LC-LC-
Biotin (Pierce/ThermoFisher, Rockford, IL) in PBS pH 6.5 at 4uC.
Excess biotinylation reagent was removed using Pepclean C-18 spin
columns (Pierce/ThermoFisher, Rockford, IL). Biotinylated pep-
tides were coupled to kinetics grade streptavidin high binding
biosensors (Fortebio, Menlo Park, CA) at several different
concentrations. Sensors coated with peptides were allowed to bind
to E protein in PBS with 0.02% (v/v) Tween-20 and 1 mg/ml BSA
at several different E protein concentrations. Binding kinetics were
calculated using the Octet QK software package, which fit the
observed binding curves to a 1:1 binding model to calculate the
association rate constants. E protein was allowed to dissociate by
incubation of the sensors in PBS. Dissociation curves were fit to a
1:1 model to calculate the dissociation rate constants. Binding
affinities were calculated as the kinetic dissociation rate constant
divided by the kinetic association rate constant.
Post-infection treatment focus forming unit assay
Approximately 200 FFU of DENV-2 without peptide was
allowed to bind and enter target cells for 1 h at 37uC as described
for the focus forming unit assay. Unbound virus was then removed
by rinsing with PBS and peptide was added to the cells for 1 h at
37uC. Cultures were washed again in PBS and agarose overlays,
incubation, and immunological detection was conducted as
described for the focus forming unit assay.
Post-binding treatment focus forming unit assay
Approximately 200 FFU of DENV-2 were allowed to attach to
cells for 45 min at 4uC, and then rinsed with cold PBS before
peptide was incubated with the target cells for 45 min at 4uC. The
cells were rinsed again with cold PBS, and agarose overlays,
incubation, and immunological detection were conducted as
described for the focus forming unit assay.
Hemagglutination inhibition assay
Hemagglutination inhibition (HI) was performed according to
[39] adapted to microtiter plates.
Virus:cell binding inhibition assay
Binding inhibition assays were modified from Thaisomboonsuk,
et al [40].}. Briefly, LLC-MK2 monolayers were rinsed in 4uC
DMEM containing 0.8% BSA and 25 mM HEPES, pH 7.5. Virus
was incubated at 4uC with peptides, control anti-dengue serum, or
heparan sulfate in DMEM/BSA/HEPES for one hour before
adding to the monolayers for 2 hours at 4uC. Monolayers were
rinsed 3 times with cold DMEM/BSA/HEPES media prior to
RNA extraction using the Qiagen RNeasy mini kit (Valencia, CA)
per manufacturers instructions. Quantitative, real time, reverse
transcriptase polymerase chain reaction (qRT-PCR) was conduct-
ed utilizing the Roche Lightcycler RNA Master SYBR Green 1
qRT-PCR kit (Basel, Switzerland), using primers Den_F (TTA-
GAGGAGACCCCTCCC) and Den_R (TCTCCTCTAACCT-
CTAGTCC) from Chutinimitkul et al [41].}. and the following
cycling conditions: 1 h at 61uC, 30 s at 95uC, followed by 45
cycles of: 5 s at 95uC, 20 s at 61uC, and 30 s at 72uC. Cp values
were used to estimate infectious units according to a standard
curve. Independent assays were repeated three times, in duplicate
or triplicate.
Design of Entry Inhibitor Peptides
www.plosntds.org 3 June 2010 | Volume 4 | Issue 6 | e721Analysis
Graphs were generated using KaleidaGraph v.3.6 graphing
software (Synergy Software, Reading, PA). Statistical analyses
were performed using the GraphPad Prism 4.0 software package
(GraphPad Software, San Diego, CA). P values less than 0.05 were
considered significant.
Results
Computational optimization of hinge region peptide
inhibitors
We had previously identified several E protein regions where
peptides mimicking the E protein sequence might function as
inhibitors. Several of these mimic peptides did not show
substantial DENV inhibitory activity [9]. These included a
peptide derived from the domain II fusion sequence (DN80,
corresponding to amino acids 96–114 in the DENV-2 E protein)
and two overlapping peptides derived from the domain II hinge
region (DN57 and DN81, corresponding to amino acids 205–223
and 205–232, respectively). Predictions from crystal structures
[11,14,15], as well as the previously confirmed inhibitory activity
of an analogous WNV domain II hinge region peptide [9] lent
support to the idea that the domain II hinge region was an
attractive target for inhibition. Energy minimized peptides with
sequences computationally optimized for structural stability and
binding to the target regions, as evaluated by our residue-specific
all-atom probability discriminatory function (RAPDF), were
selected for further characterization and evaluation. These
sequences generally had the best RAPDF scores (or ‘‘pseudoener-
gies’’) for structural stability and binding, much better (lower) than
the original wild type sequences (see Table 1 for original and
optimized sequences.). These sequences, DN57opt, DN80opt and
DN81opt, were selected for synthesis and evaluated for antiviral
activity.
Computational design and optimization of novel peptide
inhibitors
To identify additional novel peptide inhibitors and their
corresponding targets, a 20 residue sliding window that moved
from the N to the C terminus of the DENV-2 strain S1 E protein
(PDB ID 1OAN) in 10 residue acid increments was evaluated by a
structural stability (pseudoenergy) optimization protocol using the
RAPDF. A Metropolis Monte Carlo search algorithm [38] was
used to change each amino acid in the 20 residue window to one
of the 19 other naturally occurring amino acids, and the stability of
each corresponding peptide in the context of the entire E protein
structure was evaluated. Our approach identified four E protein
regions with the potential for the highest in situ binding affinities.
These correspond to DENV-2 strain S1 E protein amino acids
41–60, 131–150, 251–270, and 351–370 (see Figure 1) that were
selected for synthesis and antiviral testing (1OAN1, 1OAN2,
1OAN3, and 1OAN4).
Inhibition of DENV-2
In order to verify the effectiveness of the binding optimiza-
tion process and peptide design, synthesized peptides were
tested for antiviral activity against DENV-2 strain NG-C in a
focus forming unit (FFU) reduction assay. DENV-2 strains S1
(GenBank accession number M19197.1) and NG-C (GenBank
accession number AF038403.1) share 98% amino acid
sequence identity in the E protein and the majority of
differences are conservative. Dose response curves generated
for the optimized peptides DN57opt, DN80opt, and DN81opt
are shown in Figure 2A. The domain II region peptides,
DN57opt and DN81opt displayed IC50 values of 861 mMa n d
3666 mM( m e a n6 sem) respectively, while no inhibition of
infection was observed with t h ef u s i o nr e g i o np e p t i d e ,
DN80opt. Correspondingly, maximum inhibition of 97% and
57% was achieved at 20 mMa n d5 0mM for DN57opt and
Table 1. Sequences and IC50 values of peptides.
Name LOCATION Sequence IC50 (mM)
DN57wt 205–232 AWLVHTQWFLDLPLPWLPGADTQGSNWI --*
DN57opt RWMVWRHWFHRLRLPYNPGKNKQNQQWP 861
DN57opt-scram RWRHLKKMQRLQPRNPNWPGQFWVHYNW --
DN80wt 96–114 MVDRGWGNHAGLFGKGSIV --*
DN80opt MVIVQHQWMQIMRWPWQPE --
DN81wt 205–223 AWLVHRQWFLDLPLPWLPG --*
DN81opt RQMRAWGQDYQHGGMGYSC 3666
1OAN1wt 41–60 LDFELIKTEAKQPATLRKYC ND
1OAN1 FWFTLIKTQAKQPARYRRFC 764
1OAN1-scram QQCFRFPALRKKATYTRFWI --
1OAN2wt 131–150 QPENLEYTVVITPHSGEEHA ND
1OAN2 YPENLEYRVYITPHPGEEHH --
1OAN3wt 251–270 VVLGSQEGAMHTALTGATEI ND
1OAN3 EWSKHREGRWHTALTGATEI --
1OAN4wt 351–370 LITVNPIVTEKDSPVNIEAE ND
1OAN4 WHTVEPIVTEKDRPVNYEWE --
Names and sequences for previously tested wild type peptides are denoted with an asterisk [9], computationally designed peptides, wild type sequence peptides, and
scrambled control peptides are shown. 50% inhibitory concentrations (IC50 values 6 sem) determined from sigmoidal curve fits to the dose response curves in Figure 2
are given for DN57opt, DN81opt, and 1OAN1. Tested peptides that did not achieve 50% inhibition are noted with a dashed line. Peptides that were not tested for
antiviral activity are noted ND (no data).
doi:10.1371/journal.pntd.0000721.t001
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inhibition of DENV-2 compared to their non-optimized
counterparts, with DN57opt and DN81opt showing a nearly
14 fold and a 2 fold increase, respectively, in inhibition of
DENV-2 at equivalent concentrations [9]. The most active
inhibitor, DN57opt was chosen for further study. A scrambled
version of DN57opt (DN57optscr) did not display inhibition at
any concentration tested (Figure 2B). Four de novo designed
peptides, 1OAN1, 1OAN2, 1OAN3, and 1OAN4 were also
tested for inhibitory activity using the same FFU reduction
assay (Figure 2C). 1OAN1 was found to be an effective
inhibitor of DENV-2 infection with an IC50 of 764 mMa n da
maximum inhibition of 99% at 50 mM. A scrambled version of
1OAN1 (1OAN1scr) did not inhibit infection by DENV-2 at
any concentration tested (Figure 2D). In addition to these full
dose response inhibition experiments using approximately 100
infectious units of virus, both the DN57opt and 1OAN1
peptides were also capable of inhibiting 4,000 infectious units of
virus (data not shown).
Peptide toxicity
Because toxicity could result in a decrease in focus formation
and be interpreted as evidence of antiviral activity, the inhibitory
peptides and their scrambled versions were assessed for cellular
toxicity. Confluent monolayers of LLC-MK2 cells used in FFU
reduction assays were exposed to increasing concentrations of
peptide before measuring mitochondrial reductase activity using
an MTT mitochondrial reductase activity assay (Figure 3). When
we initially performed these assays to exactly mimic the focus
forming unit assay by waiting five days after peptide exposure, we
saw no evidence of toxicity at any concentration of any peptide
(data not shown). However, we found that a shorter post-
exposure incubation time revealed a subtle toxicity on the part of
one of the peptides. Apparently, waiting more than 24 h post-
exposure gives the cells a chance to recover and conceals this
effect. At 24 h post-exposure, DN57opt was found to be mildly
toxic to cells at 40 mM (one-way ANOVA with Dunnet’s post hoc
test, P=0.0004, N=18), so only inhibitory data using lower,
nontoxic concentrations was considered. Peptides DN57optscr,
Figure 1. Locations of predicted peptides on the DENV-2 E protein primary sequence. (A) The DENV-2 E protein is shown linearly from N
to C terminus. The three domains are color coded above, domain I is shown in red, domain II is yellow, and domain III is in blue according to [46]. The
calculated RAPDF scores of a sliding window of 20 amino acid peptide sequences are shown graphically by vertical black lines. Four major high
binding regions are predicted, from amino acids 31–70, 121–160, 241–270, and 341–380, respectively, corresponding to the locations of peptides
1OAN1, 1OAN2, 1OAN3, and 1OAN4. The locations of the other optimized peptides are indicated by three horizontal black lines, amino acids 96–114
is DN80opt, 205–223 is DN81opt, and 205–232 is DN57opt. (B) Structure of dimeric dengue E protein in the pre-fusion conformation showing
locations of inhibitory peptides. Top, side, and bottom views are shown. Structures are color coded as above. Black and grey residues show the
positions of the 1OAN1 and DN57opt peptides respectively. (C) Structure of monomeric dengue E protein in the low pH post-fusion conformation.
Inner (interacting) and outer surfaces are shown.
doi:10.1371/journal.pntd.0000721.g001
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tested (one-way ANOVA, P.0.05).
DN57opt and 1OAN1 cause changes to the surface of
DENV-2 virus
Cryoelectron microscopy (cryoEM) was used to visualize the
effect of the DN57opt and 1OAN1 peptides on DENV-2 viral
particles. Control dengue virions exhibited the normal, nearly
smooth outer surface typical of mature flaviviruses [42]. The
surfaces of the virus particles werebecome followingrough after
treatment with peptides, implying a possible rearrangement of the
envelope glycoproteins (Figure 4). The treated virions no longer
showed icosohedralsymmetry,Attemptsto reconstructthe structure
of virus complexed with DN57opt and 1OAN1 structures by
imposing icosahedral symmetry failed, indicating the viruses are no
longer icosahedral. Control treatments with equivalent DMSO
alone did not produce this morphological alteration.
DN57opt and 1OAN1 bind to soluble DENV-2 E protein
Biolayer interferometry was performed to examine binding of
the peptides to purified, truncated DENV-2 E protein. Amino
terminally biotinylated peptides were immobilized onto strepta-
vidin biosensors and then the association and dissociation of
truncated E protein with the immobilized peptides was
monitored. The interactions of three different concentrations
of truncated E protein to peptides DN57opt and 1OAN1 are
shown (Figure 5). A buffer blank containing no E protein was
run for each peptide. The affinities of the peptides for the
truncated E protein were calculated with a 1:1 binding model:
DN57opt KD=1.2 610
2660.6610
26 M( m e a n 6sd), 1OAN1
KD=4.5 610
2762.0610
27 M. While the data for the 1OAN1
peptide show a lower KD, these numbers are not statistically
different (unpaired student’s T-test, P=0.16, N=3). The
association rate constants were: DN57opt ka=8.0 610
26
5.0610
2 M
21s
21,1 O A N 1k a=3.9 610
361.5610
3 M
21s
21.
Figure 2. Inhibition of DENV-2 in vitro. Increasing concentrations of optimized inhibitor peptides and corresponding scrambled peptides of
identical composition were tested against DENV-2 in a focus forming unit reduction assay. (A) Optimized peptides (B) DN57opt and corresponding
scrambled peptide of identical composition (C) Novel peptides (D) 1OAN1 and corresponding scrambled peptide of identical composition. Error bars
are 6sem.
doi:10.1371/journal.pntd.0000721.g002
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7.7610
2461.7610
24 s
21,1 O A N 1k d=1.6 610
2360.26
10
23 s
21.W eh a v ep r e v i o u s l yu s e dt his system to characterize
the binding affinities of several human monoclonal antibodies
for DENV E proteins [43].
Treatment of cells with DN57opt and 1OAN1 post-
infection does not inhibit replication of DENV-2
In order to determine if the peptides were exerting their effects
on post-entry steps in the virus replication cycle, DENV-2 was
allowed to infect LLC-MK2 cells before peptide was added to the
cells (Figure 6). No inhibition of viral replication was observed at
any concentration of DN57opt (Figure 6A) or 1OAN1 in these
assays (Figure 6B), indicating that the peptides are not acting at a
post-infection step.
Treatment of cells with DN57opt and 1OAN1 after virus
binding to cells but before entry inhibits DENV-2
infection
Since we had determined that inhibition with both peptides
occurs at a viral entry step, we asked if infection could still be
inhibited after virus had bound to the surface of target cells. We
bound virus to cells at 4uC, then treated with increasing
concentrations of DN57opt or 1OAN1 before warming the cells
back to 37uC and allowing the infections to progress (Figure 6C
and D). Inhibition of viral entry was observed for both peptides
when added to the virus after it was bound to target cells.
DN57opt and 1OAN1 block virus binding to target cells
To determine if the peptides interefere with virus:cell interac-
tions, we conducted two different experiments. We first performed
Figure 3. Inhibitory peptide toxicity in vitro. Increasing concentrations of peptides were tested in an MTT mitochondrial reductase activity assay.
Error bars are 6 sd. (A) DN57opt (B) Scrambled version of DN57opt (C) 1OAN1 (D) Scrambled version of 1OAN1. * denotes a statistically significant
difference from the no peptide control.
doi:10.1371/journal.pntd.0000721.g003
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inhibition of the ability of viral antigen to agglutinate red blood
cells (data not shown). To further investigate virus:cell binding in a
more relevant system, we treated virus with DN57opt or 1OAN1,
bound the virus to cells, and washed the cells repeatedly at 4uC
before measuring the amount of virus remaining on the cells by
quantitative rt-PCR. Both peptides showed evidence of ability to
block virus:cell binding compared to control virus without peptide
(Figure 7). Treatment of virus with pooled human anti-dengue
serum or heparan sulfate similarly showed reduced cell binding.
Discussion
We have used computational methods to design multiple
peptide inhibitors of the DENV E glycoprotein. Importantly, out
of seven peptides synthesized and tested, two peptides with high
activity and one peptide with intermediate activity were identified.
A high resolution crystal structure of the pre-fusion conformation
of the DENV-2 E [14] was used as the starting point to generate in
situ energy minimized peptides. Two distinct approaches were
used for the design of these peptides. First, we built upon previous
work targeting DENV fusion peptide and domain II hinge regions
with naturally occurring E protein sequences from these regions
[9]. No inhibitory activity was found for the optimized fusion
peptide region sequence (DN80opt), indicating that this region
may not be a promising target mechanistically for DENV peptide
inhibitors. Since an analogous, naturally occurring WNV domain
II hinge region peptide was shown to be inhibitory against WNV
[9], we reasoned that a more tightly binding analog of this region
in the DENV E protein could be designed and might have
Figure 4. Cryoelectron microscopy. Purified and concentrated virus was prepared with or without incubation with peptides and then flash frozen
for imaging. Panels show (A) virus only, (B) virus incubated with DN57opt, (C) virus incubated with 1OAN1. Scale bars indicate 100 nm.
doi:10.1371/journal.pntd.0000721.g004
Figure 5. Peptide:E protein binding assay. Biolayer interferometry was used to assay the binding of the peptides to truncated E Protein. The
association and dissociation of increasing concentrations of truncated E protein to peptides DN57opt (A) and 1OAN1 (B) are shown. A buffer blank
(PBS, 0.02% Tween-20, 0.1% BSA) containing no E protein was run for each peptide. The affinity of the peptides for the truncated E protein was
calculated (DN57opt KD=1.2610
2660.6610
26 M (mean6sd), 1OAN1 KD=4.5610
2762.0610
27 M).
doi:10.1371/journal.pntd.0000721.g005
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identified two distinct binding-optimized peptide sequences to this
region with antiviral activity, DN57opt and DN81opt. This
supports previous predictions of hinge region inhibitors and the
proposed mechanism of fusion based on hinge region movements
[11,14,15]. The second approach to designing peptide inhibitors
was to identify peptides with non-native sequences derived from E
protein regions that are highly stable in terms of structure and
binding as evaluated by an all-atom scoring function (RAPDF).
This identified four regions that were used to derive additional
optimized peptides (Figure 1). Of the four resulting peptides tested,
one, 1OAN1, was identified as having antiviral activity. This
confirms the use of the sliding window RAPDF minimization
approach for finding tightly binding protein ligands [23,24]. It is
perhaps not surprising that computational binding optimization
increased the activity of previously inactive peptides that were
based on naturally occurring E protein sequences. Naturally
occurring sequences have multiple balancing selection pressures
that may limit their binding stability in vivo. The combined use of
primary sequence prediction tools [9] and structural optimization
tools [23,24] should be a valuable approach for finding binding
partners and inhibitors for other protein targets.
Neither peptide showed inhibitory activity when added directly
to cells after infection had already occurred, indicating that the
peptides were acting during an entry step in the virus life cycle,
and sequence scrambled versions of the two most active peptides
were inactive, confirming sequence specific activity. Both peptides
also block virus:cell binding, but are still capable of inhibiting
infection even when added after virions have already bound to the
surface of target cells.
CryoEM was used to visualize the effect of the peptides on
DENV-2 virions. The surface of virions appeared to change from
smooth to rough after incubation with the antiviral peptides. This
suggests that there may be an alteration of the arrangement of the
surface envelope protein (Figure 4). Biolayer interferometry was
used to measure the kinetics of binding between the peptides and
Figure 6. Post-infection and post-binding peptide treatments. Treatment of cells with increasing concentrations of (A) DN57opt and (B)
1OAN1 after DENV-2 has infected cells shows no significant inhibition. Treatment with (C) DN57opt or (D) 1OAN1 after DENV-2 has bound to LLCMK-2
cells at 4uC for one hour inhibits infection. Error bars are 6sem.
doi:10.1371/journal.pntd.0000721.g006
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showed a direct interaction between the peptides and DENV-2 E
protein with affinities in the 1 mM range and relatively fast on/off
rates. The cryoEM images demonstrate that these inhibitory
peptides probably cause structural deformations in intact viral
particles, but do not provide information about the kinetics of
these changes. It is possible that the peptides trap the viral E
proteins in some conformation that is part of the normal breathing
of the viral particles, and that this interferes with cell binding and
entry.
The DN57opt and 1OAN1 peptides were designed for
optimized binding to the pre-fusion E structure and we show
direct evidence for this interaction, both with the purified,
monomeric E protein, and with virion particles. These peptides
likely function by displacing portions of the E protein and
interfering with normal cell binding or the structural changes
during entry. Although separate in the primary protein sequence,
the regions targeted in the design the DN57 and 1OAN1 peptides
are partially adjacent to each other in the crystal structure, with
the C terminus of the 1OAN1 region occupying a pocket
surrounded by the DN57 region (See Figure 1). We stress that
we do not know the structures of the bound and inhibited peptide/
E protein complexes, but these structures may shed light on the
mechanistic details of cell binding and fusion. Taken together, our
results support the hypothesis that both of these peptides interact
directly with DENV-2 E proteins and are entry inhibitors.
Despite difficulties with oral administration and degradation in
the digestive tract, peptides may make useful antiviral agents when
targeted against viral envelope proteins. Directing inhibitors to
viral surface proteins avoids the major difficulty of crossing cellular
membranes in order to reach the target. For example, peptide
inhibitors of intercellular viral targets, such as proteases or
polymerases, would need to cross the cell plasma membrane,
and in the case of flaviviruses, possibly internal membrane bound
Figure 7. Quantitative reverse transcriptase PCR virus:cell binding. Virus pre-incubated with either DN57opt or 1OAN1 shows reduced
binding to cells compared to control virus without peptide. Pre-incubation of virus with pooled human anti-dengue serum or heparan sulfate
similarly shows reduced cell binding. * Indicates a significant difference (p,0.05) from all others by 1-way ANOVA followed by Tukey’s posthoc test.
doi:10.1371/journal.pntd.0000721.g007
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T-20 (Fuzeon) is a peptide, and in the context of a chronic
infection, repeated life-long injections are problematic. DENV is
an acute infection and most severe DENV infections require
intravenous fluid support, facilitating delivery of anti-DENV
peptides by this route.
We have established the existence of multiple, distinct inhibitory
peptides targeting the DENV E glycoprotein and confirmed the
utility of rational design using structural data for developing
DENV E protein inhibitors. Applications of this strategy should
also be possible for the generation and refinement of lead
compounds for other viral envelope fusion proteins. It would be
optimistic to propose that any single antiviral would provide an
effective treatment for DENV given the enormous genetic
variability of the four serotypes and multiple substrains. Different
classes of inhibitors targeting the E protein and other DENV
targets [44,45], could form the basis for the development of a
combination treatment plan to combat this disease.
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